Daratumumab Efficacy and Side Effects

Daratumumab is a revolutionary drug used to treat multiple myeloma (Multiple Myeloma), a malignant bone marrow tumor. Its efficacy and side effects are both topics worthy of attention.

Efficacy:

1.Anti-cancer effect: The main effect of daratumumab is to target the CD38 receptor in the immune system, which is overexpressed on the surface of abnormal plasma cells in patients with multiple myeloma. By binding to the CD38 receptor, daratumumab triggers the immune system's attack and destruction of cancer cells. This helps reduce the number of malignant plasma cells and prolongs patient survival.

2.Enhance drug efficacy: Daratumumab is often used in combination with other anti-cancer drugs and treatments to further improve efficacy. This combination therapy helps reduce cancer cell resistance and improves the durability of treatment.

3.Improving quality of life: Patients with multiple myeloma usually experience symptoms such as anemia, bone pain, and infection, and the use of daratumumab can improve these symptoms and improve the patient's quality of life.

4.Expanding the scope of application: In addition to multiple myeloma, daratumumab has also shown potential in the treatment of other leukemia and lymphoma types, providing a new direction for broader tumor research and treatment.

Side effects:

1.Risk of infection: Daratumumab can reduce the function of the immune system, making patients susceptible to infection. This may include bacterial, viral and fungal infections. Therefore, signs of infection need to be monitored closely and precautions taken during use.

2.Anemia and thrombocytopenia: Daratumumab may cause anemia (low hemoglobin levels) and thrombocytopenia (reduced number of platelets), which may cause fatigue and easy bruising, increasing the risk of bleeding.

3.Allergic reactions: When using daratumumab, patients may experience allergic reactions, including fever, rash, chills, headache, shortness of breath, etc. Therefore, patients are often premedicated before treatment to reduce the risk of allergies.

4.Cardiovascular problems: Some patients may experience high blood pressure or other cardiovascular problems, which require regular monitoring.

5.Respiratory tract infection: Respiratory tract infection is a common discomfort during treatment. Patients may experience symptoms such as sore throat, cough, and shortness of breath.

6.Other discomforts: There are other common discomforts such as nausea, vomiting, diarrhea, headaches and musculoskeletal pain.

It should be noted that the side effects of daratumumab vary from individual to individual, and most side effects are manageable. Doctors will weigh the risks and benefits of treatment based on the patient's specific situation and provide the necessary support and care to ensure the patient gets the best possible outcome. Patients should actively communicate with the medical team during treatment so that any discomfort or complications can be addressed promptly. Overall, daratumumab represents the future of personalized therapy and offers new hope for patients with multiple myeloma and other related diseases.

Daratumumab has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price is about more than 5,000. Medical insurance reimbursement must meet the reimbursement conditions. For specific prices and medical insurance policies, please consult the local hospital pharmacy or medical insurance bureau. Currently, there is only the original drug of daratumumab in foreign countries. The cheaper one is the Turkish original drug, which costs around 5,000. The ingredients and efficacy are consistent with the domestic original drug.